ALLK News and Press, Allakos Inc. From 05/27/22

Gainers: Fanhua (FANH) +7%. Ocular Therapeutix (OCUL) +5%. ThredUp  (TDUP) +5%. Cara Therapeutics (CARA) +3%. LegalZoom.com (LZ) +3%. Losers: Eton Pharmaceuticals (ETON) -21%. Allakos (ALLK) -7%. Accolade (ACCD) -5%. Sono Group  (SEV) -5%. FTC Solar (FTCI) -4%. For furth...

Allakos (NASDAQ:ALLK) declines 1.5% during after hours on $250M worth shares shelf offering. Company will determine when they sell shares of our common stock, which may be sold on a continuous or delayed basis directly to or through agents, dealers or underwriters. The stock has mar...

Allakos press release (NASDAQ:ALLK): Q1 GAAP EPS of -$3.60 misses by $1.78. Allakos ended the first quarter of 2022 with $246.7 million in cash, cash equivalents and marketable securities. For further details see: Allakos GAAP EPS of -$3.60 misses by $1.78

REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financia...

Gainers: Evelo Biosciences, Inc. (EVLO) +5%. CymaBay Therapeutics Inc. (CBAY) +5%. Allakos Inc. (ALLK) +5%. Diversified Healthcare Trust (DHC) +4%. Angi Inc. (ANGI) +3%. Losers: Dogness (International) Corporation (DOGZ) -5%. MaxCyte, Inc. (MXCT) -4%. FTC Solar, Inc. (FTCI...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

Shares of Allakos (NASDAQ: ALLK) fell 17.3% in February, according to data from S&P Global Market Intelligence . The biotech stock lost ground as investors continued to move out of risky, speculative plays. In December, Allakos published devastating trial data for its li...

Allakos press release (NASDAQ:ALLK): Q4 GAAP EPS of -$1.73 misses by $0.38. Allakos ended the fourth quarter of 2021 with $424.2 million in cash, cash equivalents and marketable securities. For further details see: Allakos GAAP EPS of -$1.73 misses by $0.38

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...